Shedir Pharma Srl Unipersonale
MIL:SHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
US |
Shedir Pharma Srl Unipersonale
Revenue
Shedir Pharma Srl Unipersonale
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shedir Pharma Srl Unipersonale
MIL:SHE
|
Revenue
€59.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
Revenue
€19.1m
|
CAGR 3-Years
46%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
Revenue
€2.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
Shedir Pharma Srl Unipersonale
Glance View
Shedir Pharma Group SpA operates as a holding company which engages in the research and development of nutraceuticals and medical devices. The company is headquartered in Mercato San Severino, Salerno and currently employs 71 full-time employees. The company went IPO on 2019-07-23. The firm markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.
See Also
What is Shedir Pharma Srl Unipersonale's Revenue?
Revenue
59.4m
EUR
Based on the financial report for Dec 31, 2023, Shedir Pharma Srl Unipersonale's Revenue amounts to 59.4m EUR.
What is Shedir Pharma Srl Unipersonale's Revenue growth rate?
Revenue CAGR 5Y
5%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Shedir Pharma Srl Unipersonale have been 11% over the past three years , 5% over the past five years .
